The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
[EN] BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS<br/>[FR] HÉTÉROCYCLES BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE FGFR4
申请人:INCYTE CORP
公开号:WO2016134314A1
公开(公告)日:2016-08-25
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
申请人:Bifulco, JR. Neil
公开号:US20140378481A1
公开(公告)日:2014-12-25
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
Inhibitors of the fibroblast growth factor receptor
申请人:Bifulco, Jr. Neil
公开号:US08802697B2
公开(公告)日:2014-08-12
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.